BioSpace News Archive

Aspen Neuroscience today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for ANPD001 for the treatment of Parkinson’s disease (PD) to improve motor function.

Adela, Inc. is presenting data demonstrating the feasibility of using its platform for ctDNA quantification and prognostic prediction in head and neck cancer (HNC) and renal cell carcinoma (RCC), at the European Society for Medical Oncology (ESMO) 2023 Congress.

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced an upcoming presentation at Neuro2023 on the design of ORION, a planned global, Phase 3 clinical trial of AMX0035 (sodium phenylbutyrate and taurursodiol [PB&TURSO]) in progressive supranuclear palsy (PSP).

The Sabin Vaccine Institute has launched a Phase 2 clinical trial for its vaccine candidate against the lethal Marburg virus.

MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company” or “MustGrow”) will be participating in next week’s Annual Biocontrol Industry Meeting

Olympus Corporation, a global medical technology company committed to making people’s lives healthier, safer and more fulfilling, announced today the market launch of its next-generation EVIS X1™ endoscopy system, which will be on display and demonstrated Oct. 22-24 during the American College of Gastroenterology (ACG) annual meeting in Vancouver, Canada.

Adial Pharmaceuticals, Inc. announces it has been awarded a key patent combining the use of the Company’s proprietary genetic diagnostic to detect select genotypes for genetically target treatment of alcohol use disorder and opioid use disorder with the Company’s lead investigational new drug product AD04.

Pleural Dynamics, a medical device company that is building solutions for chronic, recurrent fluid collections in the body, today announced that the Company has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the ACES™ Automatic Continuous Effusion Shunt System.

Johnson & Johnson announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2023 of $1.19 per share on the company’s common stock.

American Regent announces the launch and availability of Potassium Phosphates Injection, USP, which is FDA-approved and therapeutically equivalent to Potassium Phosphates.1 Potassium Phosphates Injection, USP is indicated as a source of phosphorus: